Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2021-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown.

We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin 100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2 diabetes during a standardized meal and measured plasma concentrations of GLP-1

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Copenhagen
• Collaborator: Hvidovre University Hospital
• Treatments: Glucagon; Glucagon-Like Peptide 1; LCZ 696; Sacubitril and valsartan sodium hydrate drug combination; Sitagliptin Phosphate; Valsartan

Criteria

Inclusion Criteria:

• Type 2 Diabetes

• Oral Antidiabetics Medicine Only

• Body Mass Index of 25-35

• Type 2 Diabetes

Exclusion Criteria:

• acute diseases within the two weeks

• chronic diseases

• smoker

• alcoholism, drug addiction or recent weight loss

• blood donation within the last 3 months